Objective: To determine rates of axillary dissection (ALND) and nodal recurrence in patients eligible for ACOSOG Z0011. Background: Z0011 demonstrated that patients with cT1-2N0 breast cancers and 1 to 2 involved sentinel lymph nodes (SLNs) having breast-conserving therapy had no difference in locoregional recurrence or survival after SLN biopsy alone or ALND. The generalizability of the results and importance of nodal radiotherapy (RT) is unclear. Methods: Patients eligible for Z0011 had SLN biopsy alone. Prospectively defined indications for ALND were metastases in !3 SLNs or gross extracapsular extension. Axillary imaging was not routine. SLN and ALND groups and radiation fields were compared with chi-square and t tests. Cumulative incidence of recurrences was estimated with competing risk analysis. Results: From August 2010 to December 2016, 793 patients met Z0011 eligibility criteria and had SLN metastases. Among them, 130 (16%) had ALND; ALND did not vary based on age, estrogen receptor, progesterone receptor, or HER2 status. Five-year event-free survival after SLN alone was 93% with no isolated axillary recurrences. Cumulative 5-year rates of breast þ nodal and nodal þ distant recurrence were each 0.7%. In 484 SLN-only patients with known RT fields (103 prone, 280 supine tangent, 101 breast þ nodes) and follow-up !12 months, the 5-year cumulative nodal recurrence rate was 1% and did not differ significantly by RT fields. Conclusions: We confirm that even without preoperative axillary imaging or routine use of nodal RT, ALND can be avoided in a large majority of Z0011-eligible patients with excellent regional control. This approach has the potential to spare substantial numbers of women the morbidity of ALND.
M
anagement of breast cancer patients with clinically negative (cN0) axillary lymph nodes has evolved over the past 2 decades, from the routine use of axillary lymph node dissection (ALND) to sentinel lymph node (SLN) biopsy alone, reserving ALND for those with positive SLNs. 1 Management evolved further when the American College of Surgeons Oncology Group (ACO-SOG) Z0011 trial demonstrated that ALND need not be routine for patients with positive SLNs; 889 patients with cT1-2N0 breast cancers and 1 to 2 positive SLNs treated by breast-conserving therapy (BCT) with whole breast irradiation (WBRT) were randomized to SLN biopsy (SLNB) alone versus ALND.
2 At 6.3 years' follow-up, there were no differences in nodal recurrence (<1% in both arms) or in any category of survival.
3 Z0011 was practicechanging, but generated controversy. Critics suggested that these results may not be widely applicable and that the Z0011 patients were not representative of breast cancer patients as a whole because the majority of those enrolled were postmenopausal women with estrogen receptor (ER)-positive cancers. There were also concerns that follow-up was insufficient, and that although Z0011 specified the use of tangent field irradiation alone, the low rates of nodal recurrence observed after SLNB alone were in part due to the use of nodal RT in a proportion of the study patients. 4, 5 Beginning in 2010, we prospectively applied the Z0011 eligibility criteria in our clinical practice to all cN0 patients undergoing BCT with planned WBRT. We have previously reported that among our first 287 Z0011-eligible patients, 84% avoided ALND. 6 Here we report our expanded series of 793 consecutive Z0011 patients, focusing on the rate of ALND and on locoregional outcomes, stratified by type of RT.
METHODS
In August 2010, we began to apply the results of ACOSOG Z0011 to the management of the axilla at Memorial Sloan Kettering Cancer Center (MSKCC). Women with cT1-2N0 invasive breast cancers undergoing BCT and having 1 and 2 positive SLNs by routine hematoxylin and eosin (H&E) staining had SLNB only. Indications for ALND were prospectively defined as metastases in 3 or more SLNs, matted nodes, or nodes with gross extracapsular extension.
Preoperative axillary imaging was not routine. If axillary imaging before referral showed that 1 to 2 nodes were abnormal, needle biopsy was not performed. When !3 abnormal nodes were seen, a fine needle aspiration (FNA) of the most suspicious node was performed, and if malignant, ALND was performed. Patients with cN0 disease, but biopsy-proven nodal metastases, were managed with SLNB as above, and have been reported previously. 7 Intraoperative SLN frozen section was eliminated, and patients were From the advised that a second surgery for ALND might be necessary. Management no longer employed the MSKCC nomogram to estimate the risk of additional positive nodes after SLNB. 8 We anticipated that all patients would receive the adjuvant systemic therapy and WBRT that are part of standard care for node-positive patients undergoing BCT. ALND remained standard management for SLN-positive patients undergoing mastectomy, and those with palpable nodal metastases. To mirror the Z0011 eligibility criteria, we excluded all patients receiving neoadjuvant therapy and all patients with nodal disease detected only by immunohistochemistry. This study was approved by the MSKCC Institutional Review Board.
We prospectively collected clinical and demographic data for all eligible patients treated by 14 different breast surgeons during the study period. Positive ER and progesterone (PR) receptors were defined as the presence of staining in !1% of tumor cells. Human epidermal growth factor receptor 2 (HER2) positivity was defined as 3þ staining by immunohistochemistry and/or a FISH ratio >2. Data on RT fields were obtained from radiation treatment summaries and/ or port films. Nodal RT was defined as inclusion of the ipsilateral level III axillary and supraclavicular nodes, with or without internal mammary nodes, within the portals.
Chi-square tests and t tests were used to compare characteristics of the SLN and ALND groups and radiotherapy fields. Competing risk analysis was used to estimate the cumulative incidence of distant, breast þ nodal, breast only, and nodal þ distant recurrences from the time of surgery. 9 All statistical analysis was performed with SAS 9.4 (SAS Institute, Cary, NC) and R 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) statistical software. P values were 2-sided, and values <0.05 were considered significant.
RESULTS
From August 2010 through December 2016, 793 patients met Z0011 eligibility criteria, had BCT, and had SLN metastases. Patient characteristics are summarized in Table 1 . The median patient age was 58 years, the median clinical tumor size was 1.7 cm, and 84% of patients had hormone receptor-positive, HER2-negative cancers. Systemic adjuvant therapy was given to 97% of patients and RT to 94%. Median follow-up for the entire cohort was 29 months (range 2-76). In all, 130 (16%) patients had ALND, most commonly for metastases in !3 sentinel nodes (n ¼ 88) or for SLN with extracapsular tumor extension (n ¼ 34). Surgeon/patient preference accounted for ALND in 8 patients otherwise eligible for SLNB alone, with 6 of these 8 in our initial 2 years' experience. One or more ''high-risk'' features, defined as age <50 years, HER2-positive, or triple negative breast cancer were present in 288 patients. The remaining 505 patients were aged 50 or older with hormone receptor-positive, HER2-negative cancers. The frequency of ALND did not differ significantly for the ''high-risk'' and non-high-risk groups (16% vs 17%, respectively; P ¼ 0.81).
In comparing the patients who had ALND and those who did not (Table 1) , there were no significant differences in age, tumor histology, tumor grade, or biologic subtype (as approximated by ER, PR, and HER2 status). Patients requiring ALND had significantly larger tumors (2.2 vs 1.6 cm; P < 0.0001) and were significantly more likely to have SLNs with microscopic extracapsular tumor extension (82% vs 31%; P < 0.0001). More patients in the ALND group received chemotherapy plus endocrine therapy, and fewer received endocrine therapy alone, reflecting their higher risk for distant recurrence (P ¼ 0.001). Only 3% of patients in each group did not receive some form of systemic therapy. There were no differences between groups in the use of RT (P ¼ 0.13).
The 5-year event-free survival for the SLNB-only group is 93% [95% confidence interval (CI) 89%-94%]. There have been no first-event (isolated) axillary recurrences. Among 8 nodal recurrences, 4 were coincident with ipsilateral breast tumor recurrence and 4 were synchronous with distant metastases. Among the 4 patients with breast and axillary nodal recurrence, 3 had not received radiotherapy and the median time to recurrence was 9.5 months (range 3-27). Among the 4 patients with nodal and distant recurrence, 1 was axillary, 2 were supraclavicular, and 1 involved both supraclavicular and internal mammary nodes. The cumulative incidence of recurrence by type of event for all patients is shown in Fig. 1 . Distant recurrence was the most common and had a 5-year cumulative incidence of 5% (95% CI 3% -7%). The median time to distant recurrence was 18.5 months (n ¼ 24, range 1-67 months). The 5-year cumulative rates of breast þ nodal, and nodal þ distant recurrences were 0.7% (95% CI 0%-1%) and 0.7% (95% CI 0%-2%), respectively, with a median time to any nodal recurrence of 25 months (n ¼ 8, range 3-67months). There were no nodal recurrences in the ALND group. The 5-year rate of breast-only recurrences was 1.6% (95% CI 0% -3%). At last follow-up, 746 patients (94%) were alive and free of breast cancer, 18 were alive with metastatic breast cancer, 11 had died of breast cancer, 7 were alive with other cancers, 6 had died of other cancer while free of breast cancer, and 5 were dead of an unknown cause.
To better stratify the risk of nodal recurrence, we examined a subset of 509 patients treated with SLNB alone with known RT fields and follow-up of at least 12 months. We excluded 25 who received nonstandard treatment (23 with no RT and 2 with partial breast RT), leaving 484 for analysis. Of these, 103 (21%) had prone breast RT, 280 (58%) had supine tangent breast RT, and 101 (21%) received breast and nodal RT. Patients selected for nodal RT had more highrisk features than those treated prone or with tangent fields alone ( Table 2) . At a median follow-up of 37 months (range 12-75), there have been 5 nodal recurrences among this subset; 4 nodal and distant and 1 breast and axillary. The 5-year cumulative rate of nodal recurrence was 1% (95% CI 0%-2%) and did not differ significantly 
Cumulative incidence of recurrence by type of event (n ¼ 793). The 5-year cumulative incidence of distant metastases was 5%. The rate of both breast and nodal and nodal and distant recurrence at 5 years was 0.7%, and the rate of breast-only recurrence was 1.6%.
by RT fields ( Table 2 ). Nodal recurrence was seen in 1% of patients treated prone, 1.4% of those treated supine, and in none of those receiving breast þ nodal RT.
DISCUSSION
Here we demonstrate in a large series of patients, selected only on the basis of Z0011 eligibility criteria, that the morbidity of ALND was avoided in 84%. The results of retrospective studies that have addressed this question, summarized in Table 3 , vary widely, with ALND avoided in 9% to 75% of patients. 5, [10] [11] [12] [13] This variation is not at all surprising, as these studies vary by denominator (all patients vs all node-positive patients vs all node-positive patients having BCT), by operation (SLNB vs ALND), and by the failure to distinguish between SLN and non-SLN metastases. The Z0011 eligibility criteria for omission of ALND specified metastases in 2 SLN, and since additional nodal metastases were found in 27% of patients randomized to ALND, it can be assumed that an equal number of patients randomized to the SLNB-only arm had additional axillary metastases, which were successfully controlled without further surgery. 3 Retrospective studies which do not distinguish between metastases in the SLN and the non-SLN minimize the potential benefit of adopting the Z0011 approach.
Some controversy surrounds the subject of preoperative axillary imaging, which we have elected not to do in our Z0011-eligible patients. Among 425 of our Z0011-eligible patients with abnormal axillary imaging (on mammography, ultrasound, or MRI), 70% had 1 to 2 positive nodes and could avoid ALND.
14 Among 141 of our Z0011-eligible patients with a positive image-guided axillary needle biopsy, 47% had 1 to 2 positive nodes and could avoid ALND. 7 These data confirm that preoperative axillary imaging and even a positive axillary needle biopsy are inadequate to make the decision for ALND, and that for Z0011-eligible patients, a negative clinical examination of the axilla is sufficient.
In our prospective study of Z0011-eligible patients, only the number of SLN metastases or extracapsular extension could be considered in the decision to perform ALND, and we did not apply any additional ''high-risk'' selection criteria such as patient age, ER status, or HER2 status. This decision was based on previous studies which found that nodal recurrence after ALND was not related to patient age or hormone receptor status. 15, 16 Our results support that decision; although our study, like Z0011, largely comprised patients who were older and ER positive, the rate of ALND was no higher among patients who were ''high risk'' by younger age and/or ERnegative and/or HER2-positive disease. These results confirm previous work demonstrating that patients at higher risk for systemic relapse do not necessarily have a heavier nodal disease burden. 17, 18 These results are also consistent with the 10-year outcomes of the Z0011 trial, in which younger age and ER negativity were significantly associated with locoregional recurrence, but event rates did not differ between the ALND and SLNB-only arms, and the majority of the locoregional events were ipsilateral breast, not nodal, recurrences. 3 Further, an exploratory analysis of Z0011 has found no differences in 10-year overall survival by ER status or by axillary treatment. 19 To what extent did node field RT contribute to the excellent locoregional control of Z0011? Although the Z0011 protocol specified RT to breast only, an audit by Jagsi et al 20 of a subset of Z0011 patients for whom complete RT data were available found that 19% received nodal RT and that nodal RT was equally frequent in the ALND and SLNB-only arms. Like Z0011, 21% of our patients received nodal RT, and the use of nodal RT increased with the number of positive SLNs. Risk factors for local recurrence, including extracapsular extension, lymphovascular invasion, and larger tumor size, were more common among our patients receiving nodal RT. Of note, our patients treated by WBRT without nodal RT were not a uniquely favorable subgroup: about half had lymphovascular invasion and 17% (prone RT) to 28% (supine tangent RT) had microscopic extracapsular tumor extension in their SLN, despite which nodal recurrence of any type (isolated or combined) was rare. Although the AMAROS (After Mapping of the Axilla: Radiotherapy or Surgery) trial 21 demonstrated that locoregional recurrence and survival did not differ among patients with 1 to 2 SLN metastases randomized to nodal RT versus ALND, the results of ACOSOG Z0011 and our own study strongly suggest that routine nodal RT for SLN-positive patients treated with SLNB alone need not be mandatory.
To our knowledge, this is the first confirmation of the findings of ACOSOG Z0011 in clinical practice and indicates that nodal recurrence rates are extremely low, despite relatively infrequent use of nodal RT. The strengths of this study include its large patient population, prospective design, uniform treatment algorithm, and detailed information regarding the use of systemic therapy and RT fields. Moreover, the similar frequencies of nodal RT use in our study (21%) and ACOSOG Z0011 (19%) indicate that radiation oncology practices between the 2 studies were similar. Our study has some limitations. Single-institution data from a group of high-volume breast surgeons may not be widely representative, but given that our results mirror those of ACOSOG Z0011 (in which participant surgeons varied widely by geography and case volume), we do not think that this is a major limitation. Our median follow-up of 3 years (used to calculate rates of nodal recurrence) is relatively short, but since the median time to regional node recurrence in the ACOSOG Z0011 trial was 4 years and only a single nodal recurrence was observed after 76 months, 3 we are highly unlikely to observe a substantial increase in isolated nodal recurrences with further follow-up. Finally, we must emphasize that our results cannot be extrapolated beyond the Z0011 selection criteria (cT1-2N0, BCT, 1-2 SLNþ, WBRT, systemic therapy). New trials are asking whether ALND can be avoided for SLN-positive patients treated by mastectomy 4 or for patients who are SLN-positive after neoadjuvant chemotherapy, 22 and it remains unclear if ALND can be avoided for SLN-positive patients treated with partial breast RTor with no RT at all. For these patients, a positive SLN remains at present an indication for ALND.
CONCLUSIONS
Here we confirm the findings of ACOSOG Z0011 in a large prospective study, and demonstrate that without preoperative axillary imaging, the use of additional selection criteria, or routine use of nodal RT, ALND can be avoided in a substantial majority of Z0011-eligible breast cancer patients with excellent local, regional, and distant control of disease. Wider adoption of the ACOSOG Z0011 algorithm has the potential to spare a substantial number of women the morbidity of ALND. Thank you. My comments should and will be extremely brief because, of course, I really, really like this paper. This is an excellent study which confirms the American College of Surgeons Oncology Group Z0011 trial in so many ways but also extends and informs that trial as well.
First, it demonstrates prospectively the applicability of the randomized Z0011 results. 84% of nearly 800 consecutive node positive women could avoid the morbidity and expense of an axillary dissection. Further, the results of this study confirms the extraordinarily low axillary recurrence rates seen in Z0011. Not 1 patient in this study had an isolated axillary node nodal recurrence.
In addition, this study demonstrated that women with highrisk factors like young age, HER2 positivity, and triple negative breast cancer have low regional recurrence without axillary dissection. In Z0011, HER2 status was not recorded. Importantly, in this study, HER2 was recorded, clearly extending the applicability of omission of axillary dissection to this previously considered highrisk group.
Finally, this study provides a glimpse at the impact of variations in nodal irradiation techniques that have been implicated by some to have achieved such good results among Z0011-eligible patients without axillary dissection.
So, rather than continue to applaud this study, I will ask some minor questions relevant to the Memorial experience specifically, and I will ask Dr Morrow to speculate further about the nonoperative management of axillary metastases.
Z0011, unfortunately, did not define gross extracapsular extension. In your study, 34 patients underwent axillary dissection for this reason. How did you define gross extracapsular extension? 2 mm doesn't sound that gross. Is a 2-mm deposit in a lymphatic approaching a lymph node considered extracapsular extension?
Your group has previously shown the prognostic impact of extracapsular extension greater than in 2 mm. 2 mm doesn't not sound that gross. However, does prognostic impact require axillary dissection? Will these patients benefit or are we overtreating them?
Surgeons in Z0011 determined the need for excision of additional lymph nodes by intraoperative palpation. In your study, if an ultrasound showed more than 2 suspicious lymph nodes, you performed a dissection. Do you believe it is necessary to have a preoperative ultrasound to aid in the decision for axillary management?
In the randomized Z0011 study, variations in irradiation fields led to considerable confusion and the speculation that excellent local regional control was due to the use of high tangents or third fields. In your study, you saw a similar rate of different nodal irradiation techniques; however, in your study, over 100 women were treated with prone irradiation, which does not irradiate lymph nodes, and even. Even in this group, you saw very few axillary recurrences. Can you speculate how such excellent results are achieved without resection or irradiation? To me, it appears that nodal irradiation provides very little benefit to this selected group of patients. How do you feel?
Response from Dr M. Morrow (New York, NY):
Thank you, Dr Giuliano. Regarding extracapsular extension, gross extracapsular extension was defined as identifying a matted ball of nodes intraoperatively or nodes in which tumor was clearly growing out of the node into the axillary fat. And, as you saw, that was an infrequent finding in this clinically node-negative population.
What was much more frequent was microscopic extracapsular extension, which was not an a priori indication for axillary dissection and was defined as tumor extending from the node through the capsule. We did not count microscopic deposits in lymphatics as extracapsular extension.
What we have demonstrated previously in a retrospective study of about 1700 patients was that if you have more than 2 mm of extracapsular extension in the sentinel node, the likelihood of having 4 or more additional positive nodes in the axilla is 33%. If you have less than 2 mm, it goes down to 9%. And if you have no extracapsular extension, it is only 3%.
So extracapsular extension is clearly a marker of nodal tumor burden. Whether that translates into the need for axillary dissection remains an open question, because, as you are well aware, microscopic extracapsular extension was not included in Z0011, or, for that matter, AMAROS. So we are planning on following this cohort of patients with microscopic extracapsular extension who were not dissected until they have more events and we can look more closely at whether or not that should be an indication for axillary dissection.
Regarding the question ''Do I advocate preoperative axillary imaging for selecting patients for a Z0011 approach?'', the answer is a most emphatic ''Absolutely not.'' The patients in our series who had preoperative axillary imaging came to us from the outside with that imaging or, in some cases, needle biopsies already done.
While we used a fairly conservative definition when we initiated this study, because it made a lot of people nervous, what we have since demonstrated again in a retrospective study of about 400 patients is that if you have patients in whom you see abnormal nodes on imaging, 70% of those patients are still eligible for a Z0011 approach, and even if they have a positive needle biopsy, 50% of those can be spared axillary dissection. So by getting axillary imaging and sticking needles in things, all you do is increase the likelihood that the patient will have an unnecessary axillary dissection, not to mention waste money.
Finally, regarding the interesting question of our prone irradiation group, I would point out that the patients who were treated prone were the lowest-risk group of the 3 groups. So they are not exactly the same as the other 2 groups. Having said that, we have known for the last 35 years based on NSABP B-04, where patients got no radiotherapy and no systemic therapy, that only one-third of patients who had axillary node disease left behind developed clinical axillary failure. So not all axillary disease becomes clinically evident. I think that, plus the very high use of systemic therapy in this population, is what accounted for our low rates of axillary recurrence.
What I think we still need to find out, though, is whether or not failure to irradiate the nodes at all is in any way associated with decreased survival as would be suggested in MA20, and I think we will find that out from ongoing trials looking at no axillary dissection in mastectomy patients.
